The New Rules of Drug Pricing, Access, and Value

April 29, 2021 11:00 AM - 12:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 4/29/2021 11:00:00 AM 4/29/2021 12:00:00 PM The New Rules of Drug Pricing, Access, and Value

While the biopharma industry’s response to COVID-19 – creating and launching multiple breakthrough innovations in record time – has generated enormous confidence and respect for biopharma, it has also reinvigorated the drug pricing debate. Now, more than ever, it’s essential for companies to have a strategic and robust approach to pricing.

In this virtual Forum, Laurie Halloran (President & CEO of Halloran Consulting Group), Laura Randa (Chief Executive Officer, Randa BioPharma Solutions), Jennifer Petrillo Billet (Director, Sage Therapeutics) and Alex Santini (Senior Vice President of Market Access, Nektar Therapeutics)  will share their guidance and expertise on developing and implementing drug pricing, value, and access strategies. Topics will include: 

  • The importance of planning, with a focus on late-stage clinical trials
  • Best practices for working with payors
  • Market access and reimbursement – at home and abroad


Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only.


NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

 Webinar, click "live-stream" button to view
Director, Department for Health Economics and Outcomes Research and Value Demonstration, Sage
Jennifer Petrillo Billet PhD is a Director at Sage Therapeutics in the Department for Health Economics and Outcomes Research and Value Demonstration, based in Cambridge MA. She leads the HEOR strategy for the NMDA portfolio, which is exploring indications in Huntington’s Disease, Alzheimer’s Disease, and Cognitive Impairment in Parkinson’s Disease. She is responsible for driving the Global strategy, including identifying patient-centric outcomes measures relevant to patients, payers, and providers. Jennifer has over 15 years of deep expertise in COA qualitative and quantitative analyses focusing on the US and EU markets, translating benefits for patient access. She has considerable expertise in the development and qualification of Clinical Outcomes Assessments (COAs) across all disease areas. As a research assistant on the only qualified COA listed under the FDA’s Drug Development Tool Qualification Program, the EXACT-PRO, she led drug sponsors, clinicians, academics, and the FDA to develop a daily diary to measure exacerbations of chronic obstructive pulmonary disease (COPD). This experience remains transformative, in terms of FDA awareness and payer relevance, in how she drives other COA strategy initiatives for Sage. Jennifer received her Bachelor of Science degree in Economics from the Pamplin College of Business at Virginia Tech, and her PhD in Health Services Research and Policy from the London School of Hygiene and Tropical Medicine. She has published and presented extensively on COA/PRO instruments and utilities, across a range of leading journals including Chest, Clinical Gastroenterology and Hepatology, Current Medical Research and Opinion, JAMA Ophthalmology, Neuro-Ophthalmology, MS Journal, Pharmacoeconomics, Quality of Life Research, and Value in Health.